Transplant tech startup Tevosol closes $2 mln seed round
Tevosol, an Edmonton-based medical device maker, has closed a $2 million seed-stage financing, bringing total funding to $6.3 million. The round's investors were not identified. Spun out of the University of Alberta in 2015, Tevosol is the developer of the ex-vivo organ support system (EVOSS), which assists surgeons with organ transplantation. Led by CEO Ron Mills, Tevosol will use the funds raised to complete a proof-of-concept human trial, expand its team, and accelerate development of its portable perfusion device for lungs. The company said it will next seek financing to support manufacturing, clinical investigation and commercial launch.
14 August 2019•2 mins read
